CHRS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CHRS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Coherus BioSciences's cost of goods sold for the three months ended in Dec. 2023 was $84.6 Mil. Its cost of goods sold for the trailing twelve months (TTM) ended in Dec. 2023 was $159.0 Mil.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Coherus BioSciences's Gross Margin % for the three months ended in Dec. 2023 was 7.6%.
Cost of Goods Sold is also directly linked to Inventory Turnover. Coherus BioSciences's Inventory Turnover for the three months ended in Dec. 2023 was 1.31.
The historical data trend for Coherus BioSciences's Cost of Goods Sold can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cost of Goods Sold is the aggregate cost of goods produced and sold, and services rendered during the reporting period. It excludes Total Operating Expense, such as Depreciation, Depletion and Amortization and Selling, General, & Admin. Expense.
Cost of Goods Sold for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $159.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus BioSciences (NAS:CHRS) Cost of Goods Sold Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Coherus BioSciences's Gross Margin % for the three months ended in Dec. 2023 is calculated as:
Gross Margin % | = | (Revenue | - | Cost of Goods Sold) | / | Revenue |
= | (91.524 | - | 84.567) | / | 91.524 | |
= | 7.6 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Cost of Goods Sold is also directly linked to another concept called Inventory Turnover:
Coherus BioSciences's Inventory Turnover for the three months ended in Dec. 2023 is calculated as:
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 84.567 | / | 64.694 | |
= | 1.31 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher inventory turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate inventory turnover. An average inventory is a better indication.
Thank you for viewing the detailed overview of Coherus BioSciences's Cost of Goods Sold provided by GuruFocus.com. Please click on the following links to see related term pages.
Dennis M Lanfear | director, officer: President and CEO | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Michael Lee Ryan | director | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Mcdavid Stilwell | officer: Chief Financial Officer | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Bryan J Mcmichael | officer: See Remarks | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, REDWOOD CITY CA 94065 |
Paul Reider | officer: Chief Commercial Officer | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Jill O'donnell-tormey | director | C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Charles W. Newton | director | 46 FREDRICK AVENUE, ATHERTON CA 94027 |
Lee Nisley Newcomer | director | 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Vladimir Vexler | officer: Chief Scientific Officer | 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Vincent R Anicetti | officer: Chief, Quality & Compliance | COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY CA 94065 |
Jean-frederic Viret | officer: Chief Financial Officer | ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080 |
Mark Stolper | director | 150 COTNER AVENUE, LOS ANGELES CA 90025 |
Alan C Mendelson | director | ALAN C MENDELSON, 135 COMMONWEALTH DR, MENLO PARK CA 94025 |
Kimberly Jo Tzoumakas | director | 1170 FAIRFAX STREET, BIRMINGHAM MI 48009 |
From GuruFocus
By sperokesalga 06-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.